drugset

drugset / Trial / NCT00451672

The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism

NCT00451672 ↗

Phase 4 Unknown 25 enrolled National Taiwan University Hospital

Non-randomizedSingle-groupOpen-labelTreatment

Summary

we propose that bromocriptine may be an alternative treatment of primary aldosteronism, both APA and BAH.

Timeline

Start: 2007-01
Primary completion: —
Completion: 2007-12

Publications

Background Chang HW, Chu TS, Huang HY, Chueh SC, Wu VC, Chen YM, Hsieh BS, Wu KD. Down-regulation of D2 dopamine receptor and increased protein kinase Cmu phosphorylation in aldosterone-producing adenoma play roles in aldosterone overproduction. J Clin Endocrinol Metab. 2007 May;92(5):1863-70. doi: 10.1210/jc.2006-2338. Epub 2007 Feb 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bromocriptine	Small molecule	—	—

Indications